Remove business series observer-business-profile
article thumbnail

AstraZeneca and MSD’s Lynparza combo bags FDA approval for prostate cancer

Pharmaceutical Technology

Safety and tolerability were in line with that observed in prior trials and the known profiles of the medicines. Dave Fredrickson, executive vice president of AstraZeneca’s oncology business unit, claimed that these results can satisfy a critical unmet need for new BRCAm mCRPC treatments.

article thumbnail

Top Performing Drug – Dupixent (April Edition)

PharmaShots

137 industry trials, 114 of which were interventional, 22 observational, and 1 expanded access trial. While the efficacy and safety profile of Dupixent is well-established for atopic dermatitis more broadly, these positive results are the first demonstrating the impact on specific and heavily used areas of the body.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Top Performing Drug – Trikafta/Kaftrio (May Edition)

PharmaShots

10 Interventional trials and 17 Observational trials. Continued research is needed to better understand its safety profile and any potential long-term risks. We would be more than happy to provide you with more information and discuss how our services may benefit your business.

article thumbnail

Uncovering The First Year of Medical School with Dr. Tim Do | The Physician Pharmacist Podcast

The Physician Pharmacist

The Physician Pharmacist Podcast originated as a seven-part mini-series that explores the journey of pharmacists who transitioned to careers in medicine. Dr. Do shares his approach to applying broadly to schools based on their applicant profile and the percentage of out-of-state applicants they accept.